Octreotide  

CAS :79517-01-4 

Octreotide-treatedgroupsshowasignificantreductioninthetumorvolumewhencomparedwithsalinegroup.Octreotide-PPSG(1.4mg/kg,i.p.)showsgreaterantitumoreffectthanOctreotide-soln(100μg/kg,i.p.).Octreotide-treatmentsresultsinsignificantinhibitoryeffectontheexpressionlevelsofSSTR2andSSTR5inprimaryHCC-bearingratscomparedwiththesalinegroup.Octreotide-PPSGappChemicalbookearstoinhibittheexpressionofSSTR2andSSTR5toagreaterextentthanthatofOctreotide-solntreatedgroup.Atestdoseofoctreotideacetatesignificantlydecreasestheserumgastrinleveltoapproximatelyonethirdofthebaselinein2hrandtheeffectlastedapproximatelyfor6hr.Onday21,treatmentwithsustained-releaseformulationofoctreotideacetatea(5mgintramuscular,q4wk)isinitiated.